What the safety reports on weight-loss jabs actually show

You might have seen scary headlines this year. Things like “hundreds of deaths linked to weight-loss jabs”. If you or someone you know is thinking about these medicines, headlines like that can be frightening. So let's slow down and look at what is actually going on, using the real numbers from the UK's medicines regulator.

The short version: the UK's safety system for medicines is working exactly as it should. It is catching rare problems early, updating warnings, and telling doctors and patients what to watch for. That is a good thing, not a reason to panic. But it is still worth understanding properly, so you know what the risks really are and what to do about them.

What is a “Yellow Card report”?

In the UK, anyone — a doctor, a pharmacist, or even a patient — can report a side effect they think might be linked to a medicine. This is called a Yellow Card report, and it goes to the Medicines and Healthcare products Regulatory Agency, or MHRA for short. The MHRA is the UK government body in charge of checking that medicines are safe.

Here is the really important bit: a Yellow Card report does not prove the medicine caused the problem. It just means someone suspected a possible link, so it got looked into. People get ill or have accidents for all sorts of reasons, and some of those people will also happen to be taking a certain medicine. The MHRA itself says this clearly: reports “do not necessarily mean a medicine caused” the reaction, “only that the person making the report suspected a possible connection.”

The pancreatitis warning

In January 2026, the MHRA strengthened the safety warnings on GLP-1 medicines (the family that includes semaglutide and tirzepatide, used both for diabetes and for weight loss). The update was about a condition called pancreatitis — inflammation of the pancreas, a gland near your stomach that helps digest food and control blood sugar. It can cause severe pain and, in rare cases, be life-threatening.

Between 2007 and October 2025, the MHRA received 1,296 Yellow Card reports of pancreatitis linked to this whole family of medicines. Of those, 19 were fatal and 24 involved a severe form called necrotising pancreatitis. To put that in context, around 25.4 million packs of these medicines were dispensed in the UK over the last five years alone. So while the warning is genuinely important, the numbers show this is a rare side effect, not a common one.

The key symptom to know: severe, ongoing pain in your tummy that may spread to your back, especially with nausea or vomiting. If that happens while taking one of these medicines, the advice is to get urgent medical help straight away and tell them what you are taking.

The “200+ deaths” headlines

The news stories about “hundreds of deaths” come from Yellow Card totals across the different weight-loss and diabetes injections: tirzepatide (Mounjaro), semaglutide (Wegovy, Ozempic, Rybelsus) and liraglutide (Saxenda) between them. Added together, these come to just over 200 suspected deaths and around 158,000 suspected side-effect reports.

That sounds like a big number on its own. But researchers at UCL estimate that around 1.6 million adults in England, Wales and Scotland used one of these medicines for weight loss in a single recent year. MHRA's chief safety officer, Dr Alison Cave, put it this way: “For the vast majority of patients who are prescribed GLP-1s, they are safe and effective medicines… The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms.”

The everyday side effects are more common — and manageable

Away from the rare, serious risks, the MHRA has also reminded doctors that common side effects like sickness, vomiting, diarrhoea and constipation affect more than 1 in 10 people taking these medicines. By late 2024, there had been over 7,000 Yellow Card reports of these symptoms, with 68 serious enough to need hospital treatment — usually because of dehydration. The advice here is simple and practical: drink plenty of water, tell your prescriber if symptoms are severe, and never push through extreme sickness without getting help.

Why this matters for how you get these medicines

All of this is part of the reason these are prescription-only medicines in the UK, never something to buy casually online. A proper prescriber will check your medical history, explain the risks clearly, and monitor you as your dose changes. The MHRA has also separately warned about falsified (fake) weight-loss pens bought from unregulated websites, some of which have been found to contain the wrong ingredients entirely, including insulin — which can be dangerous for someone who does not have diabetes.

If you are considering one of these medicines, the right first step is always a proper assessment with a qualified UK clinician — whether through the NHS or a registered private prescriber — who can weigh up your own health history against these risks.

References

• GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases (link) — MHRA Drug Safety Update, 29 January 2026

• MHRA updates guidance for GLP-1 prescribers and patients (link) — MHRA press release, 29 January 2026

• GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse (link) — MHRA Drug Safety Update, 24 October 2024

• More than 200 deaths suspected of being linked to weight-loss jabs reported to MHRA (link) — Health Tech World, August 2026 (updated September 2026)